natgillin/translations-raw huggingface dataset:
KT10 9NW UK
KT10 9NW Velika Britanija
As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years.
Kot pri drugih antipsihotikih je priporočeno redno merjenje krvnega tlaka pri bolnikih, starejših od 65 let.
Your doctor will tell you how many OLANZAPINE CIPLA tablets to take and how long you should continue to take them.
Zdravnik vam bo povedal, koliko OLANZAPIN CIPLA tablet morate vzeti in kako dolgo naj bi jih jemali.
• Whenever the risk management system is modified,especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji ali kadar je ta sprememba posledica tega, da je bil dosežen pomembnem mejnik (farmakovigilančni ali
Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1).
Dolgoročnih posledic, povezanih s temi učinki niso preučevali in ostajajo neznani (glejte poglavji 4.8 in 5.1).
OLANZAPINE CIPLA belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Zdravilo OLANZAPIN CIPLA spada v skupino zdravil, imenovanih antipsihotiki in se uporablja za zdravljenje naslednjih bolezni:
In 44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
Pri 44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/dan ni bilo povezano s kakim razločevalnim profilom neželenih učinkov.
This leaflet was last revised in {month YYYY}
Navodilo je bilo nazadnje revidirano v {MM/YYYY}.
If you forget to take OLANZAPINE CIPLA Take your tablets as soon as you remember.
Če ste pozabili vzeti zdravilo OLANZAPIN CIPLA Vzemite tablete, kakor hitro se spomnite.
Date of first authorisation: 14 November 2007 Date of latest renewal: 01 October 2012
Datum podaljšanja dovoljenja za promet: 01. oktober 2012
Smokers The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.
Kadilci Začetnega odmerka in razpona odmerkov za nekadilce ni treba rutinsko spreminjati glede na kadilce.
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16O zvišanih plazemskih koncentracijah prolaktina so poročali pri 47,4 % mladostnikov.
The experience in adolescents (ages 13 to 17 years) is limited to short term efficacy data in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents.
Izkušnje pri mladostnikih (starih 13 do 17 let) so omejene na kratkoročne podatke o učinkovitosti pri shizofreniji (6 tednov) in maniji povezani z bipolarno I motnjo (3 tedni), ki vključujejo manj kot 200 mladostnikov.
• If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).
- če so vam v preteklosti ugotovili težave z očmi kot je določena vrsta glavkoma (povišan tlak v
Dementia-related psychosis and/or behavioural disturbances Olanzapine is not approved for the treatment of dementia-related psychosis and/or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident.
Psihoza povezana z demenco in/ali vedenjske motnje Olanzapin ni odobren za zdravljenje bolnikov s psihozo, povezano z demenco in/ali vedenjskimi motnjami ter ni priporočljiv za uporabo pri teh skupinah bolnikov zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
In a study in breast feeding, healthy women, olanzapine was excreted in breast milk.
V študiji pri doječih zdravih ženskah se je olanzapin izločal v materino mleko.
Pharmacotherapeutic group: diazepines, oxazepines and thiazepines., ATC code: N05A H03.
Farmakoterapevtska skupina: diazepini, oksazepini in tiazepini, Oznaka ATC: N05AH03.
6.2 Incompatibilities
6.2 Inkompatibilnosti.
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking OLANZAPINE CIPLA and regularly during treatment.
Vaš zdravnik vas mora napotiti na krvne preiskave za določitev koncentracije sladkorja in določenih maščob v krvi pred začetkom jemanja zdravila OLANZAPIN CIPLA in redno tekom zdravljenja.
You should take your OLANZAPINE CIPLA tablets once a day following the advice of your doctor.
OLANZAPIN CIPLA tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
There are no data on maintenance of effect and limited data on long term safety (see sections 4.4 and 4.8).
Podatkov o vzdrževalnem učinku ni in podatki o dolgoročni varnosti so nezadostni (glejte poglavji 4.4 in 4.8).
You should not be given this medicine when breast-feeding, as small amounts of OLANZAPINE CIPLA can pass into breast milk.
Ko dojite, tega zdravila ne smete jemati, ker lahko majhne količine zdravila OLANZAPIN CIPLA prehajajo v materino mleko.
Consult your doctor if your symptoms return but do not stop taking OLANZAPINE CIPLA unless your doctor tells you to.
Če se simptomi povrnejo, se posvetujte s svojim zdravnikom, vendar ne prenehajte jemati zdravila OLANZAPIN CIPLA, če vam tega ne naroči vaš zdravnik.
It is important that you carry on taking OLANZAPINE CIPLA for as long as your doctor tells you.
Pomembno je, da nadaljujete z jemanjem zdravila OLANZAPIN CIPLA tako dolgo, kot vam naroči zdravnik.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu/
• carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your OLANZAPINE CIPLA dose.
• karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo treba spremeniti vaš odmerek zdravila OLANZAPIN
Do not stop taking your tablets just because you feel better.
Če ste prenehali jemati zdravilo OLANZAPIN CIPLA Ne prenehajte jemati tablet samo zato, ker se počutite bolje.
If this happens after you have been given OLANZAPINE CIPLA tell your doctor.
Če se vam to zgodi po tem, ko ste prejeli zdravilo OLANZAPIN CIPLA, povejte svojemu zdravniku.
• The use of OLANZAPINE CIPLA in elderly patients with dementia is not recommended as it may have serious side effects.
• Uporaba zdravila OLANZAPIN CIPLA ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.
Oral use Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo.
Absolute oral bioavailability relative to intravenous administration has not been determined
Absolutna peroralna biološka uporabnost glede na intravensko dajanje ni bila določena.
Do not use this medicine after the expiry date which is stated on the carton after Exp. Store in the original package.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu.
What you need to know before you take OLANZAPINE CIPLA
Kaj morate vedeti, preden boste vzeli zdravilo OLANZAPIN CIPLA
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels.
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina.
• unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;
• nenavadne gibe (pogost neželeni učinek, ki lahko prizadene do 1 od 10 bolnikov), predvsem obraza ali jezika;
The daily dose of OLANZAPINE CIPLA is between 5 and 20 mg.
Dnevni odmerek zdravila OLANZAPIN CIPLA je med 5 in 20 mg.
In patients with Parkinson's disease OLANZAPINE CIPLA may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo OLANZAPIN CIPLA poslabša simptome.
The starting dose and dose range need not be routinely altered for female patients relative to male patients.
Spol Začetnega odmerka in razpona odmerkov za bolnice ni treba rutinsko spreminjati glede na bolnike.
Cipla (EU) Ltd
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Cipla (EU) Ltd
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ POGLEDA IN
• blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
• krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo oteklino, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.
podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP
Children and adolescents OLANZAPINE CIPLA is not for patients who are under 18 years.
Otroci in mladostniki Zdravilo OLANZAPIN CIPLA ni namenjeno bolnikom, mlajšim od 18 let.
Marketing Authorisation Holder: Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK
Imetnik dovoljenja za promet z zdravilom: Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, Veľká Británia
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF] ≥ 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo QTcF < 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0,1 % do 1 %), brez pomembnih razlik v spremljajočih srčnih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
However, as with other antipsychotics, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.
Vendar pa je kot pri drugih antipsihotikih potrebna previdnost, kadar predpisujemo olanzapin skupaj z zdravili, za katera je znano, da podaljšujejo QTc interval, posebno pri starejših, pri bolnikih s prirojenim sindromom dolgega QT intervala, kongestivnim popuščanjem srca, hipertrofijo srca, hipokaliemijo ali hipomagnezemijo.
In placebo-controlled clinical trials (612 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively).
V kliničnih preskušanjih, kontroliranih s placebom (ki so trajali 6-12 tednov), pri starejših bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami (povprečna starost 78 let), je bilo 2-kratno povečanje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3,5 % v primerjavi z 1,5 %).
Patients treated with any antipsychotic agents, including Olanzapine Cipla, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom OLANZAPIN CIPLA, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK Tel: +44 (0)1372 461407
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, Velika Britanija Tel: +44 (0)1372 461407
6.5 Nature and contents of container
6.5 Vrsta ovojnine in vsebina.
Lactose monohydrate, Maize starch Hydroxypropyl cellulose Magnesium stearate
Jedro tablete laktoza monohidrat koruzni škrob hidroksipropilceluloza magnezijev stearat
If you take more OLANZAPINE CIPLA than you should Patients who have taken more OLANZAPINE CIPLA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Če ste vzeli večji odmerek zdravila OLANZAPIN CIPLA, kot bi smeli Bolniki, ki so vzeli večji odmerek zdravila OLANZAPIN CIPLA, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
- The other ingredients are: - Tablet core: lactose monohydrate (See also end of section 2 - important information about some of the ingredients of Olanzapine Cipla), maize starch, hydroxypropyl cellulose, magnesium stearate.
- Pomožne snovi so: - Jedro tablete: laktoza monohidrat (glejte tudi konec 2. poglavja - pomembne informacije o nekaterih sestavinah zdravila OLANZAPIN CIPLA), koruzni škrob, hidroksipropilceluloza, magnezijev stearat.
Neonates exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno z olanzapinom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
Each Olanzapine Cipla coated tablet contains either 2.5 mg, 5 mg, 7.5 mg, 10 mg or 15 mg of the active substance.
Vsaka obložena tableta zdravila OLANZAPIN CIPLA vsebuje 2,5 mg, 5 mg, 7,5 mg, 10 mg ali 15 mg zdravilne učinkovine.
Ventricular tachycardia/fibrillation , sudden death (see section 4.4)11
Prekatna tahikardija/fibrilacija, nenadna smrt (glejte poglavje 4.4) 11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter) 11
Patients treated with any antipsychotic agents, including Olanzapine Cipla, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom OLANZAPIN CIPLA, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
7 coated tablets 28 coated tablets 56 coated tablets
7 obloženih tablet 28 obloženih tablet 56 obloženih tablet
What OLANZAPINE CIPLA is and what it is used for
Kaj je zdravilo OLANZAPIN CIPLA in za kaj ga uporabljamo
OLANZAPINE CIPLA tablets contain lactose.
OLANZAPIN CIPLA tablete vsebujejo laktozo.
Patients with renal and/or hepatic impairment
Bolniki z ledvično in/ali jetrno okvaro
OLANZAPINE CIPLA 2.5 mg coated tablets OLANZAPINE CIPLA 5 mg coated tablets OLANZAPINE CIPLA 7.5 mg coated tablets OLANZAPINE CIPLA 10 mg coated tablets OLANZAPINE CIPLA 15 mg coated tablets olanzapine
OLANZAPIN CIPLA 2,5 mg obložene tablete OLANZAPIN CIPLA 5 mg obložene tablete OLANZAPIN CIPLA 7,5 mg obložene tablete OLANZAPIN CIPLA 10 mg obložene tablete OLANZAPIN CIPLA 15 mg obložene tablete olanzapin
- Tablet coat: - 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets: Opadry white containing hypromellose (E464), titanium dioxide (E171), lactose monohydrate, polyethylene glycol 3000 and glycerol triacetate - 15 mg tablets: Opadry Blue containing hypromellose (E464), titanium dioxide (E171), polyethylene glycol 6000, indigo carmine aluminium lake (E132), brilliant blue FCF aluminium lake (E133) and iron oxide black (E172)
- Obloga tablete: - 2,5 mg, 5 mg, 7,5 mg in 10 mg tablete: Opadry beli, ki vsebuje hipromelozo (E464), titanov dioksid (E171), laktozo monohidrat, makrogol 3000 in gliceriltriacetat - 15 mg tablete: Opadry modri, ki vsebuje hipromelozo (E464), titanov dioksid (E171), laktozo monohidrat, makrogol 6000, barvilo indigotin (E132), barvilo modro FCF (E133) in črni
Olanzapine Cipla 2.5 mg, 5 mg, 7.5 mg and 15 mg coated tablets are available in 28 and 56 blister packs.
OLANZAPIN CIPLA 2,5 mg, 5 mg, 7,5 mg in 15 mg obložene tablete so na voljo v pakiranjih po 28 in 56 tablet.
OLANZAPINE CIPLA has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Zdravilo OLANZAPIN CIPLA dokazano preprečuje ponoven pojav teh simptomov pri bolnikih z bipolarno motnjo, pri katerih se je manična epizoda po zdravljenju z olanzapinom izboljšala.
28 coated tablets 56 coated tablets
28 obloženih tablet 56 obloženih tablet
OLANZAPINE CIPLA coated tablets are for oral use.
OLANZAPIN CIPLA obložene tablete so za peroralno uporabo.
• iIf you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila OLANZAPIN CIPLA - če ste alergični na (preobčutljivi za) olanzapin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
MARKETING AUTHORISATION NUMBER(S)
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET.
Olanzapine is indicated for the treatment of schizophrenia.
Odrasli Olanzapin je indiciran za zdravljenje shizofrenije.
How to store OLANZAPINE CIPLA Contents of the pack and other information
5 Shranjevanje zdravila OLANZAPIN CIPLA Vsebina pakiranja in dodatne informacije
You should swallow the OLANZAPINE CIPLA tablets whole with water.
OLANZAPIN CIPLA tablete pogoltnite cele z vodo.
What OLANZAPINE CIPLA is and what it is used for What you need to know before you take OLANZAPINE CIPLA How to take OLANZAPINE CIPLA Possible side effects
Kaj je zdravilo OLANZAPIN CIPLA in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo OLANZAPIN CIPLA
The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml.
V razponu koncentracij od približno 7 do približno 1000 ng/ml je bila vezava olanzapina na plazemske beljakovine približno 93 %.
Olanzapine Cipla 10 mg coated tablets are available in 7, 28 and 56 blister packs.
OLANZAPIN CIPLA 10 mg obložene tablete so na voljo v pakiranjih po 7, 28 in 56 tablet.
3 years 6.4 Special precautions for storage
6.4 Posebna navodila za shranjevanje.
Do not drink any alcohol if you have been given OLANZAPINE CIPLA as together with alcohol it may make you feel drowsy.
Jemanje zdravila OLANZAPIN CIPLA skupaj z alkoholom Če ste dobili zdravilo OLANZAPIN CIPLA, ne pijte nobenega alkohola, saj lahko zdravilo OLANZAPIN CIPLA in alkohol skupaj povzročita občutek zaspanosti.
Opadry II White containing: Hypromellose (E464) Titanium dioxide (E171) Lactose monohydrate Polyethylene glycol 3000 Glycerol triacetate
Opadry II beli vsebuje: hipromelozo (E464) titanov dioksid (E171) laktozo monohidrat makrogol 3000 gliceriltriacetat
The following symptoms may occur in newborn babies, of mothers that have used OLANZAPINE CIPLA in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo OLANZAPIN CIPLA, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
COLD-FORMED ALUMINIUM BLISTER STRIPS
MRZLO OBLIKOVANI ALUMINISKI PRETISNI OMOTI
In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/hr, respectively).
Pri kadilcih z blagimi motnjami v delovanju jeter je bil srednji razpolovni čas izločanja (39,3 ure) podaljšan in očistek (18,0 l/h) zmanjšan tako kot pri zdravih nekadilcih (48,8 ur oziroma 14,1 l/h).
Olanzapine Cipla 7.5 mg
Olanzapin Cipla 7,5 mg
- The active substance is olanzapine.
- Zdravilna učinkovina je olanzapin.
HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; 1
V predkliničnih študijah je olanzapin pokazal razpon afinitet do receptorjev (Ki; < 100 nM) za serotonin 5-HT2A/2C, 5-HT3, 5-HT6; dopamin D1, D2, D3, D4, D5; holinergičnih muskarinskih receptorjev M1-M5; adrenergičnih 1; in histaminskih H1 receptorjev.
Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.
Redki neželeni učinki (lahko prizadenejo do 1 od 1.000 bolnikov) vključujejo , znižanje normalne telesne temperature, ki povzroči obračanje očesa, motnje srčnega ritma, nenadno nerazložljivo smrt, vnetje trebušne slinavke, ki povzroča hude bolečine v predelu želodca, zvišano telesno temperaturo in slabost, obolenje jeter, ki se kaže kot rumeno obarvanje kože in beločnic, mišične bolezni, ki se kažejo kot nepojasnjene bolečine v mišicah, podaljšano in/ali bolečo erekcijo.
Gynaecomastia/breast enlargement in males
Ginekomastija/povečan je dojk pri moških
Pharmadox Healthcare Limited KW20A Kordin Industrial Park Paola PLA 3000
KW20A Kordin Industrial Park
If you suddenly stop taking OLANZAPINE CIPLA, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Če nenadno prenehate jemati zdravilo OLANZAPIN CIPLA, se lahko pojavijo simptomi, kot so znojenje, nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
• Stroke or “mini” stroke (temporary symptoms of stroke)
• možgansko kap ali malo možgansko kap (prehodni znaki kapi)
Olanzapine Cipla 10 mg
Olanzapin Cipla 10 mg